THIS WEBSITE IS FOR BUSINESS & INDUSTRY PARTNERS. FOR CONSUMER PRODUCTS VISIT : BLIS Probiotics >
THIS WEBSITE IS FOR BUSINESS & INDUSTRY PARTNERS. FOR CONSUMER PRODUCTS VISIT : BLIS Probiotics >
As the original developers of clinically proven oral probiotic strains, BLIS owns and supplies BLIS K12TM and BLIS M18TM, proprietary S. salivarius strains native to the oral microbiome.
Our science-led platforms enable partners globally to create premium, differentiated solutions across oral health, immunity, and beyond. Rooted in nature, protected by IP, and proven in the real world.
Protecting the gateway to your whole body - the mouth.
Supporting the immune system for optimal health.
Restoring and maintaining healthy teeth and gums.
Balancing and improving our biggest organ - the skin.
Restoring and maintaining healthy teeth and gums.
Protecting the gateway to your whole body.
Oral probiotic solutions for canine companions.
Balancing and improving our biggest organ - the skin.
We are dedicated to developing, and supplying clinically validated probiotic strains that support oral and upper respiratory health.
Discovered by Professor Emeritus John Tagg, our strains are native to the human oral cavity and backed by a growing body of published clinical research.
Streptococcus salivarius K12 (BLIS K12™) is one of the most studied strains for oral and ENT health. In a 90-day study of 82 children with recurrent infection, BLIS K12™ was associated with a ~90% reduction in streptococcal pharyngeal infection episodes vs. the prior year (Di Pierro 2012). Supports throat, upper respiratory, and ENT health, and helps maintain fresh breath
Streptococcus salivarius M18 (BLIS M18™) targets Streptococcus mutans, the primary driver of dental decay, and inhibits gingipain gene expression linked to Porphyromonas gingivalis activity. Clinical studies have tracked improvements in plaque scores, gingival bleeding index, and ICDAS caries index over 12 months (Babina 2023/2024). Supports teeth and gum health.
Micrococcus luteus Q24 (BLIS Q24™) is commensal to the skin microbiome. In a 25-day study, participants using BLIS Q24™ showed reductions in pore size, sebum, and impurities, alongside increased hydration. Helps support skin health by crowding out pathogenic bacteria and maintaining skin microbiome balance.
Formulation flexibility across lozenge, chewable, and powder formats, backed by manufacturing support to help you scale from concept to shelf.
We support formulation teams from strain selection through to finished product — with the technical, regulatory, and manufacturing backing that oral care and supplement brands need to bring a probiotic product to market.
